CSBIO(SZ:300255)2022-12-07 08:34Group 1: Company Overview and Market Position - The price of heparin sodium raw materials is currently at a relatively low point, with limited downward space [2] - The new low molecular weight heparin raw material workshop has passed German GMP and US FDA certification, which is expected to become a growth point for the company [2] - Sales of low molecular weight heparin calcium injection have been steadily increasing in recent years, and the company's first generic drug, heparin sodium injection, has entered the market and is expected to achieve rapid growth [2] Group 2: Future Plans and Collaborations - The company plans to export heparin preparations to Europe and the US, having already partnered with D.Med Healthcare GmbH&Co.KG in Germany to establish a joint venture for secondary packaging to sell in the European market [2] - The first blood dialysis center is being standardized and has been completed, awaiting expert group acceptance [3] - Clinical trials for Abiraterone have entered Phase I [3] Group 3: Product Development and Regulatory Status - The supplementary application for sildenafil raw materials and formulations was submitted to the National Medical Products Administration in the first half of 2015 and has been accepted; the corresponding production workshop is completed and awaits drug registration approval and GMP certification [3] - The bidding results for low molecular weight heparin calcium injection this year have been good, with stable winning prices; the heparin sodium injection is in the gradual development stage due to its new market entry [3] - The company is currently producing cosmetic-grade and food-grade hyaluronic acid in its pilot workshop, with a new production workshop under construction [3]